J Korean Child Neurol Soc.  2014 Jun;22(2):47-51.

Efficacy and Tolerability of Valproic Acid Once Daily Dosing for Juvenile Myoclonic Epilepsy

  • 1Department of Pediatrics, Seoul National University Children's hospital, Seoul, Korea.
  • 2Department of Pediatrics, Seoul National University Bundang Hospital, Gyeonggi-do, Korea. hunminkim@hanmail.net
  • 3Pediatric Clinical Neuroscience Center, Department of Pediatrics, Seoul National University Children's hospital, Korea.
  • 4Department of Pediatrics, Seoul National University Boramae Hospital, Seoul, Korea.


The purpose of this study was to evaluate the efficacy and tolerability of extended-release valproic acid once daily dosing in juvenile myoclonic epilepsy (JME).
Medical records of patients who received valproic acid monotherapy for the treatment of JME were retrospectively reviewed. Their clinical information regarding age, gender, seizure types, underlying neurologic status, dosing regimen, response to treatment, and adverse events related to valproic acid, were analyzed. Seizure control, compliance, and adverse events rates were compared between the group of once daily dosing and the group of twice daily dosing.
Twenty one patients (11 boys and 10 girls) were included in the study. Twelve patients were taking valproic acid extended-release once daily and nine patients were taking twice a day. More than 50% decrease in myoclonic seizure was achieved in all the patients in both groups. Generalized tonic-clonic seizure was controlled in all the patients who were taking once daily while 3 patients (36%, 3/8 patients) in twice daily group had breakthrough generalized tonic clonic seizures during the 2 year period of treatment. However, there were no statistically significant differences in seizure control, compliance, and adverse event rates between the two groups.
This study demonstrated that valproic acid extended-release once daily dosing was as effective and tolerable as twice daily in the treatment of JME. Once daily dosing of valproic acid would be convenient which improve patient compliance and consequently bring better outcome in treatment of JME.


Juvenile myoclonic epilepsy; Valproic acid extended release; Effectiveness; Tolerability

MeSH Terms

Medical Records
Myoclonic Epilepsy, Juvenile*
Patient Compliance
Retrospective Studies
Valproic Acid*
Valproic Acid
Full Text Links
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr